IL-12-producing cytokine factories induce precursor exhausted T cells and elimination of primary and metastatic tumors.

ABSTRACT:

Background

Curative responses to immunotherapy require the generation of robust systemic immunity with limited toxicity. Recruitment of T cell populations such as precursor exhausted T cells (Tpex) from lymphoid tissues to tumors is a hallmark of effective treatment. However, the ability to efficiently induce this recruitment is lacking in current immunotherapy approaches. Furthermore, systemic administration of immunotherapies frequently results in dose-limiting toxicities, yielding an inadequate therapeutic window for eliciting durable responses.

Methods

In this investigation, we evaluated the safety and antitumor efficacy of locally administered interleukin 12 (IL-12) using a clinically translatable cytokine delivery platform (NCT05538624) to identify Tpex recruitment cap

SUBMITTER: Nash A 

PROVIDER: S-EPMC11962782 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature